论文部分内容阅读
APSI试验是一个随机安慰剂对照,用于评价急性心肌梗塞(AMI)后的高危患者经醋丁洛尔治疗1年后的疗效试验。 方法 从1987年4月～1988年12月,共有来自法国44所医院的607例AMI后不到22天的患者入选。对上述患者给予醋丁洛尔治疗并随访1年。但由于安慰剂组1年的死亡率明显低于事先所预计的,故试验在第2年的中期分析后曾一度中断。与安慰剂组对照,醋丁洛尔可使患者1年的总死亡率显著降低48％(P=0.019)。1995年,在APSI
The APSI trial is a randomized placebo-controlled trial to evaluate the efficacy of acebutolol 1 year after high-risk AMI. Methods From April 1987 to December 1988, a total of 607 AMI patients from 44 hospitals in France were enrolled in less than 22 days. Acebutolol was given to the above patients and followed up for 1 year. However, the one-year mortality rate in the placebo group was significantly lower than previously estimated and the trial was discontinued after the second year interim analysis. Acebutolol caused a significant 48% reduction in overall 1-year patient mortality compared with placebo (P = 0.019). In 1995, at APSI